Investing.com cites 55.4 percent return for Mater Dei stock

Published on 10/16/2026 at 01:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached BRL 448.54 million in the second quarter of 2026. Mater Dei stock posted a 55.4 percent return by October 15, 2026.

Revenue and valuation signals

Hospital Mater Dei delivered a 55.4 percent return by October 15, 2026.
Second-quarter 2026 revenue reached BRL 448.54 million, while EBITDA grew 35 percent in the first quarter.
Analysts set an average 12-month target of BRL 7.22 based on nine ratings.

Mater Dei, BRMATDACNOR4, Illustration mit AI erstellt.

Mater Dei (ISIN BRMATDACNOR4) had delivered a 55.4 percent return by October 15, 2026, after rising from BRL 4.26 to BRL 6.62 over 11 months. Investing.com attributed the comparison to its fair-value analysis.

Why the return matters

The valuation case is supported by operating figures from 2026. Mater Dei generated BRL 448.54 million in revenue in the second quarter of 2026, while earnings per share reached BRL 0.0823, according to Investing.com. The same report said EBITDA growth reached 35 percent in the first quarter of 2026, linking the improvement to efficiency gains.

Three dates shape the story

On November 1, 2025, the stock traded at BRL 4.26 when the fair-value estimate stood at BRL 6.02. On August 12, 2026, the latest release listed revenue of BRL 613.63 million and net income of BRL 44.25 million for the latest reported quarter, compared with BRL 574.96 million and BRL 33.21 million in the preceding quarter, according to Investing.com. On October 15, 2026, the valuation analysis put the accumulated return at 55.4 percent.

What does the business scale show?

Mater Dei's latest trailing-12-month profile through June 30, 2026, included BRL 2.3 billion in net revenue, BRL 141.8 million in net income and BRL 516.0 million in EBITDA. The figures came with a 6.1 percent net margin and a 22.3 percent EBITDA margin, according to Brasil 247.

Valuation remains the next test

The average 12-month analyst target is BRL 7.22, based on nine ratings, with six Buy ratings, three Holds and zero Sell ratings. The target stands above the BRL 6.28 B3 quotation shown on the financial summary page, while the reported 52-week range runs from BRL 4.13 to BRL 6.85, according to Investing.com.